An Angiotensin II Type 1 Receptor Blocker Prevents Renal Injury via Inhibition of the Notch Pathway in Ins2 Akita Diabetic Mice by Koshizaka, Masaya et al.
Hindawi Publishing Corporation
Experimental Diabetes Research
Volume 2012, Article ID 159874, 10 pages
doi:10.1155/2012/159874
Research Article
An Angiotensin II Type 1 Receptor Blocker Prevents Renal Injury
viaInhibitionoftheNotch Pathway inIns2Akita DiabeticMice
MasayaKoshizaka,1 Minoru Takemoto,2 SeiyaSato,3 HirotakeTokuyama,1
Masaki Fujimoto,2 EmikoOkabe,1 Ryoichi Ishibashi,1 TakahiroIshikawa,1
YuyaTsurutani,1 ShunichiroOnishi,1 Morito Mezawa,1 Peng He,1 Satoshi Honjo,1
ShiroUeda,4 YasushiSaito,5 and KoutaroYokote1,2
1Department of Clinical Cell Biology and Medicine, Chiba University Graduate, 1-8-1 Inohana, Chuo-ku, Chiba-shi,
Chiba 260-8670, Japan
2Division of Diabetes, Metabolism and Endocrinology, Department of Medicine, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku,
Chiba-shi, Chiba 260-8670, Japan
3Seiwa Narashino, 3-5-3 Akitsu, Narashino-shi, Chiba 275-0025, Japan
4Ueda Clinic, 1-13-18 Nobuto, Chuo-ku, Chiba-shi, Chiba 260-0032, Japan
5Chiba University, 1-33 Yayoi-cho, Inage-ku, Chiba-shi, Chiba 268-8522, Japan
Correspondence should be addressed to Minoru Takemoto, minoru.takemoto@faculty.chiba-u.jp
Received 23 September 2011; Accepted 23 October 2011
Academic Editor: Mark Emmanuel Cooper
Copyright © 2012 Masaya Koshizaka et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Recently, it has been reported that the Notch pathway is involved in the pathogenesis of diabetic nephropathy. In this study, we
investigated the activation of the Notch pathway in Ins2 Akita diabetic mouse (Akita mouse) and the eﬀects of telmisartan, an
angiotensin II type1 receptor blocker, on the Notch pathway. The intracellular domain of Notch1 (ICN1) is proteolytically cleaved
from the cell plasma membrane in the course of Notch activation. The expression of ICN1 and its ligand, Jagged1, were increased
in the glomeruli of Akita mice, especially in the podocytes. Administration of telmisartan signiﬁcantly ameliorated the expression
of ICN1 and Jagged1. Telmisartan inhibited the angiotensin II-induced increased expression of transforming growth factor β and
vascular endothelial growth factor A which could directly activate the Notch signaling pathway in cultured podocytes. Our results
indicate that the telmisartan prevents diabetic nephropathy through the inhibition of the Notch pathway.
1.Introduction
The worldwide prevalence of diabetes in all age groups was
2.8% in 2000 and is estimated to be 4.4% in 2030 [1].
The total number of people with diabetes mellitus (DM) is
expected to rise from 171 million in 2000 to 366 million in
2030. Diabetic nephropathy, a major microvascular compli-
cation of DM, is the most common cause of end-stage renal
disease (ESRD) [2]. The number of ESRD cases is expected
to increase mainly as a result of the increasing incidence of
obesity and type 2 DM.
A number of pathways such as the protein kinase C path-
way [3] and the polyol pathway [4]a sw e l la sa d v a n c e dg l y -
cationendproducts[5]havebeenreportedtoplayimportant
roles in the development of diabetic nephropathy. It has also
been reported that the renin-angiotensin system (RAS) plays
a potent role in the initiation and progression of diabetic
nephropathy [6].
A number of clinical evidences have suggested that the
blockade of the RAS by angiotensin-converting enzyme
(ACE) inhibitors (ACEIs) and/or angiotensin II type1 recep-
tor (AT1R) antagonists (ARBs) could improve renal function
or slow down disease progression in diabetic nephropathy
[7]. Furthermore, it has been reported that ACEIs and/or
ARBs inhibit the RAS and have pleiotropic eﬀects, which
improve renal prognosis.
Recently, Niranjan et al. reported that the Notch pathway
was activated in diabetic nephropathy and in focal segmental2 Experimental Diabetes Research
glomerulosclerosis (FSGS) [8]. The activation of the Notch
pathway in podocytes has been studied in genetically
engineered mice. These mice developed glomerulosclerosis
due to the activation of p53, which induced apoptosis in
podocytes. The same group also showed that pharmaceutical
and genetic blockade of the Notch pathway prevented mice
from developing diabetic and puromycin-aminonucleoside-
(PAN-) induced glomerulosclerosis.
The Notch signaling pathway is a signaling pathway that
determines cell fate [9]. Further, it is regulated by cell-cell
communication during the formation of various internal
components such as the nerves, blood, blood vessels, heart,
and hormonal glands. Notch is a transmembrane receptor
protein that interacts with ligands of the Jagged and Delta
families [10].
The aim of this study was to examine the activation of
the Notch pathway in Akita mice as well as the eﬀects of
telmisartan on the Notch pathway both in vivo and in vitro.
2.MaterialsandMethods
2.1. Reagents. Telmisartan was obtained from Nippon Boeh-
ringer Ingelheim Co., Ltd. (Tokyo, Japan). Candesartan was
purchased from Tronto Research Chemicals (North York,
Canada). Angiotensin II was obtained from Sigma-Aldrich
(St. Louis, MO). Recombinant human TGF-β1 (#240-B) and
recombinant human VEGF-A (#293-VE) were purchased
from R&D systems (Minneapolis, MN). GSI was purchased
from Calbiochem (San Diego, CA). Hoechst 33342 was from
Dojindo laboratories (Kumamoto, Japan).
2.2. Animals. Male heterozygous Ins2 Akita diabetic mice
(C57BL/6) and C57BL/6 controls were obtained from Japan
SLC Inc. (Shizuoka, Japan). Eight-week-old Akita mice and
control mice received telmisartan (5mg·kg−1·day−1)o rn o
treatment for 15 weeks (n = 8 in each group). The blood
glucose level, body weight, blood pressure, and urinary albu-
min excretion were measured every two weeks. The blood
glucose level was examined using Medisafe-Mini (TERUMO
Corporation, Tokyo, Japan), and the blood pressure was
determined by the tail cuﬀ method using Softron BP-98A
(Softron, Tokyo, Japan). In order to estimate albuminuria,
mice were individually housed in metabolic cages for 24h.
Urine was collected, and urinary albumin concentrations
were measured with a Lebis Albumin assay kit (Shibayagi,
Gunma, Japan). The blood creatinine levels, BUN, fasting
blood glucose levels, and HbA1c were measured at the time
of sacriﬁce. All experiments in this study were performed
in accordance with the Guidelines of the Animal Care and
Use Committee of Chiba University, Japan, which follows
the Guide for the Care and Use of Laboratory Animals (NIH
publication no. 85-23, revised 1985). The ethics committee
for animal research at Chiba University approved all animal
experiments.
2.3. Immunohistochemistry. The following commercially
available antibodies were used: rabbit anti-Jagged1 (1:200
dilution, sc-11376) and rabbit antihuman TGF-β1 (1:50, sc-
146)antibodieswerepurchasedfromSantaCruzBiotechnol-
ogy (Santa Cruz, CA). Rabbit anti-cleaved Notch1 antibody
(1:100, Val1744, no. 2421S) waspurchasedfromCellSignal-
ing (Danvers, MA). Rat anti-podocalyxin monoclonal anti-
body (0.5μg/mL, MAB1556) was from R&D systems. Mice
kidneys were embedded in OCT compound and frozen, and
10μm sections were made. The sections were air dried, ﬁxed
in methanol (10min on ice), rinsed in phosphate-buﬀered
Tween (PBT), and blocked for 30min with phosphate-
buﬀered saline (PBS) containing 0.5% bovine serum albu-
min (BSA). Primary antibodies were diluted in PBS con-
taining 1% BSA and were incubated with the sections
overnightat4◦C.TheslideswererinsedwithPBTforseveral
times. The ﬂuorophore-conjugated secondary antibodies
were applied for 2h. The sections were again rinsed with
PBT for several times, mounted (Vectashield Mounting
Medium with DAPI; Vector Laboratories, Inc., Burlingame,
CA), and viewed under a ﬂuorescence microscope (Axio
Observer; Leica) or a confocal laser scanning microscope
(Leica LSM5 PASCAL). The images were processed using
Adobe Photoshop.
2.4. Cell Culture. Mouse podocytes, conditionally immortal-
ized with a temperature-sensitive variant of the SV40 large
T-antigen, were kindly provided by Dr. Peter Mundel (Albert
Einstein College of Medicine, NY, USA). The preparation
and characterization of these cells have been described
elsewhere [11]. Podocytes were maintained in Roswell
Park Memorial Institute (RPMI) 1640 medium (Gibco/Life
Technologies, Grand Islands, NY, USA) supplemented with
10% fetal bovine serum (FBS; Sigma Aldrich), 100U/mL
penicillin, and 100U/mL streptomycin (Sigma Aldrich).
To propagate podocytes, cells were cultivated at 33◦C
and incubated with 10U/mL of murine recombinant γ-
interferon (Pepro Tech EC Ltd, London, UK) to enhance
the expression of the T-antigen (permissive conditions).
To induce diﬀerentiation, podocytes were cultured at 37◦C
without γ-interferon in RPMI 1640. Cells were cultured
under nonpermissive conditions for at least 11d before they
were used in the experiments. The medium was changed
every 3d to induce full diﬀerentiation. Cells at passages 12
to 18 were used for the experiments in this study.
2.5. Reverse Transcriptase-Polymerase Chain Reaction. The
expression of mRNA in podocytes was analyzed by reverse
transcriptase-polymerase chain reaction (RT-PCR). Total
RNA was extracted using an RNeasy Mini Kit (Qiagen, Hild-
en, Germany) according to the manufacturer’s instructions.
After treatment with DNase, 1μg of total RNA was reversely
transcribed using oligo dT primer, pd(T)12–18 (Invitrogen,
Carlsbad, CA), to avoid genomic contamination. The cDNA
was generated using SuperScript III Reverse Transcriptase
(Invitrogen, Carlsbad, CA). Gene-speciﬁc oligonucleotides
for the PCR analyses were designed according to the pre-
dicted cDNA sequences (http://www.ensembl.org/). The
PCR was performed in a 25μL PCR reaction containing
1μL of complementary DNA (cDNA), Taq reaction buﬀerExperimental Diabetes Research 3
Table 1: Characteristics of the experimental groups of mice.
Wild control Wild telmisartan Akita control Akita telmisartan
Blood glucose (mg/dL) 250 ±34 284 ±58 1216 ±130∗ 955 ±137∗,†
HbA1c (%) 4.3 ±0.34 .2 ±0.31 0 .8 ±1.4∗ 11.8 ±0.5∗
Body weight (g) 36.4 ±3.44 0 .7 ±9.02 0 .8 ±0.8∗ 23.2 ±1.4∗,†
Systolic blood pressure (mmHg) 109.3 ±4.79 6 .1 ±7.3 126.4 ±5.9∗ 110 ±5.1∗,†
Urinary albumin (mg/day) 21.2 ±9.41 0 .9 ±2.51 51.4 ±11.6∗ 33.8 ±8.5∗,†
Data are expressed as the mean ± standard deviation (SD). ∗P<0.01 versus wild-type control, †P<0.01 versus Akita control.
(Go Taq, Promega, Madison, WI), and 10μMo fd N T P s .T h e
primer sequences and sizes of the expected PCR products are
as follows: Hes1, 5 -CCCTGTCTACCTCTCTCCTT-3 ,5  -
AGGTGCTTCACAGTCATTTC-3 , 472bp; TGF-β,5  -TCC-
AAGAAAAAGAAAATGGA-3 ,5  -CTCTGAATCAGGTTGT-
GGAT-3 , 452bp; VEGF-A, 5 -GTGGACATCTTCCAGGA-
GTA-3 ,5  -ATCTGCAAGTACGTTCGTTT-3 , 382bp; β-
actin,5 -TCGTGCGTGACACATCAACATCAAAGAG-3 ,5  -
TGGACAGTGAGGCCAGGATG-3 , 411bp. PCR was per-
formed for 25–30 cycles. Each cycle consisted of denatu-
ration at 94◦C for 2min, annealing at 50◦C for 30s, and
extension at 72◦C for 30s. PCR ampliﬁcation was fol-
lowed by a ﬁnal extension step at 72◦C for 7min. An ali-
quot of 10μLo fe a c hP C Rp r o d u c tw a ss u b j e c t e dt oe l e c -
trophoresisona2%agarosegel(Ronza),followedbystaining
with an ethidium bromide solution (Sigma). The signals
were photographed with a charge-coupled device (CCD)
camera system (Printograph, ATTO). Densitometric analy-
ses of the ﬂuorograms were performed using an image scan-
ner (EPSON GT-X900) with ImageJ software (http://rsbweb
.nih.gov/ij/download.html).
2.6. Morphometric Analysis. Five glomeruli (n=3, in each)
were randomly selected from each specimen. The extent of
extracellular mesangial matrix was determined by quantiﬁ-
cation of the periodic-acid-Schiﬀ-staining- (PAS-) positive
area in the mesangium and divided by the glomerular tuft
area. The extracellular mesangial matrix area and glomerular
tuft area were quantiﬁed by ImageJ.
2.7. Detection of Apoptosis by Hoechst Staining and Flow
Cytometric Assays. Podocytes were treated with AII in the
presence or absence of telmisartan for 72h. After the treat-
ment, apoptosis was deﬁned as the presence of nuclear con-
densation on Hoechst staining. Alternatively, the cells were
collected, washed twice with cold phosphate-buﬀered saline
(PBS), and centrifuged at 1,000g for 5 minutes. Subse-
quently, the Annexin V/propidium iodide assay was carried
out to determine apoptosis according to the manufacturer’s
instructions(BDPharmingen)andanalyzedbyﬂowcytome-
try (FACSCalibur; BD Immunocytometry Systems, San Jose,
CA).
2.8. Statistical Analysis. Results are expressed as the mean
± standard error of the mean (SEM). Experimental points
were performed in triplicates with a minimum of three
independent experiments. An unpaired Student’s t-test was
used for comparison of two groups. P<0.05 was considered
signiﬁcant.
3. Results
3.1. Telmisartan Reduces the Urinary Albumin Excretion in
Akita Mice. First, we evaluated the eﬀect of telmisartan on
blood pressure in mice. Table 1 shows that Akita mice had
a higher blood pressure than the controls. As expected, ad-
ministration of telmisartan signiﬁcantly lowered the blood
pressure. Compared to the controls, Akita mice also had
considerably higher levels of blood glucose and HbA1c,
which eventually led to loss of body weight. Telmisartan de-
creased the blood glucose level and led to an increase in
body weight in Akita mice (Table 1). The urinary albumin
excretions were signiﬁcantly increased in untreated Akita
mice compared to wild-type controls, and administration of
telmisartan signiﬁcantly reduced urinary albumin excretion
(Table 1).
Next, we investigated the eﬀect of telmisartan on the
glomerular morphology. Expansion of the mesangial areas
was observed in Akita mice; however, telmisartan had no
profound eﬀect on the glomerular morphology as deter-
mined by light microscopy (Figure 1).
3.2.TelmisartanInhibitstheNotchPathwayandtheExpression
of TGF-β, Which Are Activated in the Glomeruli of Akita
Mice. Recently, it has been reported that the Notch pathway
is activated in podocytes in DM. Therefore, we examined
the Notch pathway in Akita mice. ICN1 staining in kidneys
revealed that the number of ICN1-positive cells in the
glomeruli was signiﬁcantly higher in Akita mice (Figures
2(a) and 2(b)). We could not observe ICN1-positive cells
other than in the glomeruli. This indicated that the Notch
pathway was activated in Akita mice, and the activation of
the Notch pathway seemed to be restricted to the glomeruli.
In order to identify cell types that were activated by the
Notch pathway within the glomeruli, we also carried out
coimmunostaining with an anti-ICN1 antibody and an anti-
podocalyxin antibody (a marker for podocytes). We local-
ized ICN1 proteins to the nuclei of the cells which were
positive for podocalyxin within the cytoplasm (Figure 2(c)).
Therefore, Notch pathway was activated in podocytes in
diabetic conditions. Administration of telmisartan signiﬁ-
cantly reduced the number of ICN1-positive cells in the
glomeruli (Figures 1(a) and 1(b)). Next, we investigated
the expression of Jagged1, which is a ligand for the Notch4 Experimental Diabetes Research
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Figure 1: Morphometric analyses of the glomeruli of Akita mice. (a) Eight-week-old Akita mice and control mice received telmisartan
(5mg·kg−1·day−1, in their drinking water) or no treatment, respectively, for 15 weeks (n = 8 in each group). After 15 weeks, the mice were
sacriﬁced, the kidneys were harvested, and periodic acid-Schiﬀ staining was performed. (b) Quantiﬁcation of sclerosis per glomerular area
was performed with the ImageJ software. ∗∗P<0.01, n.s.: not signiﬁcant.
receptor. The expression pattern of Jagged1 was quite similar
to that of ICN1 (Figure 2(d)). These results indicated that
telmisartan inhibited the Notch pathway in vivo either
directly or indirectly. It has been reported that the Notch
pathway in podocytes was activated by TGF-β signaling
[8]. Therefore, we investigated the expression of TGF-β
by immunohistochemistry. We observed upregulated TGF-
β expression in the glomeruli of Akita mice (Figure 2(e)),
especially in podocytes (Figure 2(f)). Administration of
telmisartan also suppressed the expression of TGF-β in the
glomeruli (Figure 2(e)).
3.3. Angiotensin II Activates the Notch Signaling Pathway
through Increased Expression of TGF-β and VEGF-A in Cul-
tured Podocytes. Telmisartan lowered the blood pressure
and improved the blood glucose level in Akita mice. From
these ﬁndings, we were not able to completely exclude the
possibility that the inhibitory eﬀect of telmisartan on the
Notch pathway invivowasduetoasystemiceﬀect.Therefore,
we used cultured mouse podocytes that were conditionally
immortalized in order to not only rule out the inﬂuence
of blood pressure and glucose levels but also elucidate the
mechanismbywhichtelmisartaninhibitstheNotchpathway.
Telmisartan is an AT1R blocker. For this reason, we studied
the eﬀect of angiotensin II (AII), a ligand for AT1R, on the
activation of the Notch pathway. As shown in Figure 3(a),
the mRNA expression of hairy enhancer of split homolog-
1 (Hes1), which was a target gene of the Notch signaling
pathway, increased considerably in the presence of 10−6M
AII. In addition, telmisartan inhibited the AII-induced
mRNA expression of Hes1 (Figure 3(a)). The expression of
Jagged1 mRNA was also increased in the presence of AII,
and telmisartan inhibited AII-induced mRNA expression of
Jagged1 (data not shown). We also examined the eﬀect of
candesartan, another type of AT1R blocker, and found that
candesartan inhibited the AII-induced mRNA expression of
Hes1 same as telmisartan (Figure 3(b)). It has been reported
that TGF-β and VEGF-A activate the Notch pathway [12];
therefore, the eﬀect of AII on the expression of TGF-β and
VEGF-Awasinvestigated.AsshowninFigures3(c)and3(d),
incubation with AII signiﬁcantly increased the expression of
both TGF-β and VEGF-A. Telmisartan reversed this eﬀect.
Finally, we observed the eﬀects of TGF-β and VEGF-A
on the activation of the Notch pathway and found that these
growth factors could activate the Notch pathway. However,
telmisartan had no eﬀect on the Notch pathway in the
presence of TGF-β or VEGF-A (Figure 4).
3.4. Telmisartan Suppresses the Podocyte Apoptosis Induced by
Angiotensin II. It has been reported that the activated Notch
pathway induces apoptosis to the glomerular podocytes
which eventually causes glomerulosclerosis. Therefore, we
investigated whether telmisartan could prevent podocyte
apoptosis. As shown in Figures 5(a) and 5(b), ﬂow cytometer
studies using annexin V and propidium iodide showed that
apoptotic cells were increased in the podocytes treated with
AII (12.56 ± 1.9% versus 7.09 ± 1.4% in the control group,
P<0.01), and telmisartan treatment signiﬁcantly decreased
the AII-induced apoptotic cells (8.51 ± 2.0% versus 12.56 ±
1.9% in the AII group, P<0.01). We also examined the
apoptosis by the use of Hoechst 33342 staining as shown in
Figures 5(c) and 5(d). Nuclear condensation was observed
in the podocytes in the presence of AII, and those changes
weresigniﬁcantlydecreasedwhenthepodocytes weretreated
with telmisartan. We also examined the eﬀects of γ-secretase
inhibitor (GSI) on the AII-induced apoptosis and found that
GSI, an inhibitor of Notch signaling, was able to inhibit the
AII-induced apoptosis (Figure 4). Collectively, these results
indicated that the AII induced podocytes apoptosis via
the activating Notch signaling pathway, and telmisartanExperimental Diabetes Research 5
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Figure 2: Notch pathway was activated in the glomeruli of Akita diabetic mice and telmisartan inhibited its expression. The expression of
the intracellular domain of Notch1 (ICN1) (a and c), Jagged1 (d), and transforming growth factor β (TGF-β) (e and f) were examined by
immunohistochemistry. Anti-podocalyxin (Podxl) antibody was used as a marker for podocyte. ICN-1 was localized to podocyte nuclei (c),
while TGF-β was localized to podocyte cytoplasm, respectively (f). Quantiﬁcation of ICN1-positive cells per glomeruli was performed (b).
Ten glomeruli of each specimen were randomly selected. The ICN1-positive cells within the glomeruli were counted under a ﬂuorescence
microscope. Statistical signiﬁcance was analyzed using Student’s t-test. Arrows indicated the glomerulus. Bars indicated the mean value.
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Figure 3: Telmisartan suppressed the activation of the Notch signaling pathway through inhibition of the angiotensin II type 1 receptor.
The mRNA expression of Hes1, one of the Notch target genes; transforming growth factor β (TGF-β); vascular endothelial growth factor-A
(VEGF-A) were examined by reverse transcriptase-polymerase chain reaction. (a) The podocytes were stimulated with 10−6M Angiotensin
II (AII) for 24 to 48h. The mRNA expression of Hes1 increased in the presence of AII and peaked at 24h. On the other hand, 10−6M
telmisartansuppressedtheAII-inducedmRNAexpressionofHes1(upperpanel).QuantiﬁcationoftheHes1mRNAexpressioncomparedto
theinternalcontrol(β-actin)(lowerpanel).(b)Thepodocytesweretreatedwith10−6MAIIinthepresenceorabsenceof10−8Mcandesartan
for24h.CandesartanalsosuppressedtheAII-inducedmRNAexpressionofHes1.(c)AIIincreasedtheTGF-βmRNAby2.5-foldwithin12h.
Telmisartan (10−6M) suppressed the expression of TGF-β signiﬁcantly. (d) AII increased the VEGF-A expression by 2.0-fold. Telmisartan
suppressed the expression of VEGF-A signiﬁcantly. ∗P<0.05.
inhibited podocytes apoptosis through the inhibition of
Notch signaling pathway (Figure 5(e)).
4. Discussion
In the present study, we investigated the activation of the
Notch pathway in the glomeruli (especially in the podocytes)
of Akita mice. Treatment with telmisartan signiﬁcantly re-
duced not only the urinary albumin excretion which was
usually seen as an early manifestation of diabetic nephropa-
thy but also the activation of the Notch pathway. We also
conﬁrmed that AII induced the activation of the Notch path-
wayinculturedpodocytes.IncubationwithAIIincreasedthe
expression of TGF-β and VEGF-A, and telmisartan reversedExperimental Diabetes Research 7
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Figure 4: TGF-β and VEGF-A directly activated the Notch pathway. The podocytes were stimulated with 5ng/mL transforming growth
factor β (TGF-β) or 10ng/mL vascular endothelial growth factor-A (VEGF-A) in the presence or absence of 10−6M telmisartan. The mRNA
expressionofHes1wasexaminedbyreversetranscriptase-polymerasechainreaction.(a)TGF-β increasedtheexpressionofHes1irrespective
ofthepresenceorabsenceoftelmisartan(upperpanel).QuantiﬁcationofHes1expressioncomparedtotheinternalcontrol(β-actin).TGF-β
signiﬁcantly increased the Hes1 expression within 2h by 2.1-fold (lower panel). (b) VEGF-A increased the expression of Hes1 irrespective
of the presence or absence of telmisartan (upper panel). Quantiﬁcation of the Hes1 expression compared to the internal control (β-actin).
VEGF-A signiﬁcantly increased the Hes1 expression within 2h by 1.6-fold (lower panel). ∗P<0.05, n.s.: not signiﬁcant.
this eﬀect. TGF-β and VEGF-A could directly activate the
Notch pathway.
Diabetic nephropathy, the leading cause of ESRD in the
western world and Asia, is a considerable socioeconomic
burden. Investigation of the pathophysiology and establish-
ment of a treatment for diabetic nephropathy is urgently
needed. AII is a potent vasoconstrictor hormone that is
cleaved from angiotensinogen by renin and ACE. In addition
to its known vital role in both cardiovascular and blood
pressure homeostasis, several lines of evidence implicate
a role in diabetic nephropathy. Durvasula and Shankland
have reported that high glucose activates the local RAS
in podocytes (independent of ACE activity), which led to
injury of the podocytes [13]. Therefore, RAS are locally
and systemically activated under diabetic conditions. It has
also been reported that the injury of podocytes, referred
to as podocytopathy, is a hallmark not only in diabetic
nephropathy but also in virtually all glomerular diseases
[14]. There are not many pharmacological options to treat
diabetic nephropathy; ACEIs and/or ARBs are currently the
only drugs that eﬀectively slow the progression of diabetic
nephropathy [15]. Furthermore, clinical trials demonstrated
that ARBs also lower the risk of type 2 DM compared with
otherantihypertensivetherapies.Theseobservationsindicate
thatARBscanpotentiallybeusedtoinduceeﬀectsotherthan
blood pressure lowering eﬀects. Indeed, ARBs have recently
been proven to attenuate inﬂammation and oxidative stress
and inhibit apoptosis [16]. These eﬀects are known as
pleiotropic eﬀects. In addition to the previously reported
pleiotropic eﬀects, in the present study, we identiﬁed that
telmisartan inhibited the activation of the Notch pathway.
The Notch pathway is known to control a number of cell-
fate-speciﬁc events in multiple organisms, especially during
development, and it also plays a crucial role in diseases such
ascancersandautoimmunediseases[17].Ithasbeenrecently
reported that the Notch pathway is activated in mouse
models of DM such as Lprdb/db mice (which mimics type 2
DM), in streptozotocin-treated mice (which leads to type 1
DM), and in kidney specimens from patients with DM [8].
It has also been reported that high glucose activated Notch
pathway and increased the expression of VEGF in cultured
podocyte [18]. We conﬁrmed the activation of the Notch
pathway in another diabetic animal, the Akita mouse. Our
ﬁndings support the idea that the Notch pathway is generally
activated in podocytes in DM. In recent years, GSIs received
signiﬁcant attention as drug candidates for the treatment of
Alzheimer’s disease and cancers [19]. Since GSIs are capable
of inhibiting the Notch signaling pathway, they can be used
in the treatment of diabetic nephropathy in the future. In
addition to GSIs, our data also suggest that telmisartan
inhibits the Notch pathway. To the best of our knowledge,
this is the ﬁrst report that describes the ARB-induced8 Experimental Diabetes Research
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Figure 5: Telmisartan suppressed the podocyte apoptosis which was induced by angiotensin II. The eﬀects of AII as well as telmisartan on
the podocytes apoptosis were examined by the ﬂow cytometry or by the Hoechst staining. (a, b) The podocytes were treated with 10−6MA I I
in the presence or absence of 10−6Mt e l m i s a r t a no r5m Mγ-secretase inhibitor (GSI) for 72h. Apoptosis in podocytes was determined by
low propidium iodide staining and prominent annexin V labeling using the ﬂow cytometry. AII signiﬁcantly induced podocytes apoptosis
compared to the controls (12.56 ± 1.9% versus 7.09 ± 1.4%). Telmisartan signiﬁcantly suppressed AII-induced apoptosis in podocytes
(8.51 ± 2.0% versus 12.56 ± 1.9%). GSI also signiﬁcantly suppressed that (7.89 ± 1.6% versus 12.56 ± 1.9%). Representative results of three
independent experiments were presented. ∗P<0.05, ∗∗P<0.01. (c) The apoptosis in podocytes was examined by Hoechst staining. The
podocytes were treated with 10−6M AII, 10−6M telmisartan, and 5mM GSI as indicated in the ﬁgures for 72h. Apoptosis was determined
by nuclear condensation pattern and expressed as the percentage of apoptotic cells per high-power ﬁeld. A total of 5 high-power ﬁelds
in a pericentric distribution were quantitated per well. (d) Telmisartan and GSIs suppressed the podocyte apoptosis (CT 2.3 ± 1.5%, AII
22.3 ± 2.54%, Telm + AII 6.3 ± 0.9%, and GSI + AII 3.6 ± 2.0, resp.). Telm:t e l m i s a r t a n ,∗∗P<0.01. (e) Schematic illustration of the eﬀects
of telmisartan on the Notch pathway in podocytes.Experimental Diabetes Research 9
inhibition of the Notch pathway both in vivo and in vitro.
Telmisartan is a potent and highly selective AT1R antagonist.
Furthermore, telmisartan exerted eﬀects other than the
blockade of AT1R, such as PPARγ activation [20]. Our
data showed that telmisartan improved the levels of blood
glucose, which might indicate that telmisartan functioned as
aP P A R γ agonist and improved insulin resistance in Akita
mice. Although telmisartan signiﬁcantly reduced urinary
albumin excretion, we were not able to detect profound his-
tological improvement. There might be some time diﬀerence
between the improvement in urinary albumin excretion and
the improvement histologically. Telmisartan lowered the
blood pressure and improved the blood glucose level in
Akita mice. From these ﬁndings, we were not able to com-
pletely exclude the possibility that the inhibitory eﬀect of
telmisartan on the Notch pathway in vivo was due to a
systemic eﬀect. However, we also used cultured podocytes in
order to rule out the inﬂuence of blood pressure and glucose
levels. Therefore, we argue that telmisartan could directly
aﬀect podocytes in order to inhibit the Notch pathway. We
also investigated whether candesartan, another ARB, could
suppress the Notch pathway and found that candesartan also
inhibited Notch signaling pathway. Therefore, the inhibitory
eﬀect of Notch pathway by telmisartan seems to be a class
eﬀect of ARB.
It has been reported that the genetically activated Notch
pathway in podocytes in mice activated p53 and induced
apoptosis, which led to decreased expression of the slit dia-
phragm-related protein such as nephrin, causing proteinuria
and renal dysfunction [8]. We tried to detect apoptosis by
terminal deoxyribonucleotidyl transferase dUTP nick-end
labeling (TUNEL) staining and by staining for activated
caspase 3. However, we could not observe apoptosis in the
glomeruli of Akita mice, and this could be attributed to tech-
nical reasons.
There are some limitations to this present study. First, we
were not able to completely exclude the possibility systemic
eﬀects of telmisartan for reducing Notch signal in vivo.
Second,wearenotabletoexplainthereasonwhytelmisartan
did not improve the glomerulosclerosis which was seen in
Akita mice. Third, we still do not completely understand the
biologicalsigniﬁcanceofactivatedNotchpathwayindiabetic
condition.
In summary, we showed that the Notch pathway was
activated in podocytes of Akita mice and that administration
of telmisartan inhibited the Notch pathway. Our data might
indicate that telmisartan inhibits the Notch pathway. In
addition to its blood pressure lowering eﬀect, which leads to
reduced cardiovascular morbidity and mortality, telmisartan
might improve the renal prognosis, especially in diabetic
subpopulations. Further investigations are needed to prove
this hypothesis in the future.
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